Soren Giese – General Manager, Amgen Italy
In a wide-ranging and candid conversation, Amgen Italy General Manager Soren Giese outlines the strategy he put in place to restructure Amgen’s operations in the Italian market, the company’s…
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Contact
Amgen
Via Tazzoli, 6
20154 – Milano Italia
Tel.: 0039 02 6241121
In a wide-ranging and candid conversation, Amgen Italy General Manager Soren Giese outlines the strategy he put in place to restructure Amgen’s operations in the Italian market, the company’s…
Francesco di Marco, General Manager for Amgen Italy, shares his view on the state of the Italian pharmaceutical sector, the turnaround the company has made in the country, and what…
Italy, Europe’s fourth largest pharma market at a size of EUR 23.446 billion, has a highly decentralised healthcare system, with the country’s 20 regions negotiating market access for medicines individually…
Pierre Fabre Italy’s Charles-Henri Bodin highlights how the French firm’s offering has expanded far beyond its dermo-cosmetics heritage to today encompass a wide range of pharmaceuticals, including the key growth…
Domenico Mantoan, General Manager of AGENAS, the Italian National Agency for Regional Health Services, discusses the role of the agency in Italy’s decentralised healthcare system, the National Recovery and Resilience…
Nicoletta Luppi, MSD Italia’s Senior Vice President & Managing Director details the need for healthcare reform in Italy and walks us through MSD’s portfolio priorities. In addition, she explains the…
In recent years, since the adoption of a law assuring its citizens’ right to access palliative care, Italy has given increased attention to pain management. According to Aldo Sterpone, Italy…
Aldo Sterpone, Grünenthal Italia’s General Manager, outlines the company’s focus on pain and its efforts to bring innovation to the area through R&D and acquisitions. He also explains the importance…
We spoke with Luca Crippa, CEO and Managing Director at IBSA Farmaceutici, about the company’s approach to developing new delivery technologies for existing and natural molecules, its focus on endocrinology,…
Stevanato Group’s CEO & COO, Franco Moro explaines how the over 70-year-old provider of containment and delivery solutions went public and as an established player in the vaccine space managed…
CAI is an engineering service company. Its regional manager for South Europe, Andrea Castiglioni, comments on the pharma industry’s need for commissioning and qualification services when looking to reduce time…
Merck Italia’s Managing Director & President, Jan Kirsten explains the importance of the Italian affiliate within the global organisation, Merck’s aim to strengthen its position in oncology and the challenges…
Over the past decade, the birth rate in Italy has consistently decreased, making it one of the countries with the lowest birth rates in the world but also one of…
Stanislao Caputo, GM at Aristo Pharma Italy, explains the Italian subsidiary’s strategy and how the diversification of its core business led to the acquisition of a portfolio of GSK dermo-cosmetic…
See our Cookie Privacy Policy Here
